|
Name |
2-Methyl-3-benzylidene-6,7,8,8a-tetrahydropyrrolo[1,2-a]pyrazine-1,4(2H,3H)-dione
|
Molecular Formula | C15H16N2O2 | |
IUPAC Name* |
(3Z)-3-benzylidene-2-methyl-6,7,8,8a-tetrahydropyrrolo[1,2-a]pyrazine-1,4-dione
|
|
SMILES |
CN1/C(=C\C2=CC=CC=C2)/C(=O)N3CCCC3C1=O
|
|
InChI |
InChI=1S/C15H16N2O2/c1-16-13(10-11-6-3-2-4-7-11)15(19)17-9-5-8-12(17)14(16)18/h2-4,6-7,10,12H,5,8-9H2,1H3/b13-10-
|
|
InChIKey |
SNYXWODAEROITA-RAXLEYEMSA-N
|
|
Synonyms |
CHEMBL4872269; 3-benzylidene-2-methylhexahydropyrrolo [1,2-a] pyrazine-1,4-dione; 2-Methyl-3-benzylidene-6,7,8,8a-tetrahydropyrrolo[1,2-a]pyrazine-1,4(2H,3H)-dione
|
|
CAS | NA | |
PubChem CID | 101115021 | |
ChEMBL ID | CHEMBL4872269 |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 256.3 | ALogp: | 1.7 |
HBD: | 0 | HBA: | 2 |
Rotatable Bonds: | 1 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 40.6 | Aromatic Rings: | 3 |
Heavy Atoms: | 19 | QED Weighted: | 0.721 |
Caco-2 Permeability: | -4.61 | MDCK Permeability: | 0.00003300 |
Pgp-inhibitor: | 0.016 | Pgp-substrate: | 0.001 |
Human Intestinal Absorption (HIA): | 0.06 | 20% Bioavailability (F20%): | 0.011 |
30% Bioavailability (F30%): | 0.124 |
Blood-Brain-Barrier Penetration (BBB): | 0.979 | Plasma Protein Binding (PPB): | 71.89% |
Volume Distribution (VD): | 0.514 | Fu: | 18.50% |
CYP1A2-inhibitor: | 0.426 | CYP1A2-substrate: | 0.696 |
CYP2C19-inhibitor: | 0.393 | CYP2C19-substrate: | 0.837 |
CYP2C9-inhibitor: | 0.186 | CYP2C9-substrate: | 0.207 |
CYP2D6-inhibitor: | 0.015 | CYP2D6-substrate: | 0.211 |
CYP3A4-inhibitor: | 0.087 | CYP3A4-substrate: | 0.531 |
Clearance (CL): | 3.801 | Half-life (T1/2): | 0.441 |
hERG Blockers: | 0.018 | Human Hepatotoxicity (H-HT): | 0.867 |
Drug-inuced Liver Injury (DILI): | 0.739 | AMES Toxicity: | 0.021 |
Rat Oral Acute Toxicity: | 0.265 | Maximum Recommended Daily Dose: | 0.034 |
Skin Sensitization: | 0.296 | Carcinogencity: | 0.653 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.018 |
Respiratory Toxicity: | 0.027 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC005322 | 0.515 | D06BYV | 0.409 | ||||
ENC005971 | 0.472 | D08EOD | 0.357 | ||||
ENC001087 | 0.472 | D05EPM | 0.333 | ||||
ENC005484 | 0.472 | D04ACW | 0.333 | ||||
ENC000825 | 0.472 | D07RGW | 0.324 | ||||
ENC002980 | 0.452 | D08UMH | 0.321 | ||||
ENC004695 | 0.452 | D0L1WV | 0.321 | ||||
ENC004694 | 0.452 | D03KOZ | 0.318 | ||||
ENC004892 | 0.425 | D0R6RO | 0.314 | ||||
ENC005321 | 0.408 | D05ZIK | 0.314 |